Alnylam Pharmaceuticals Inc (ALNY) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Alnylam Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Alnylam Pharmaceuticals Inc's ROI in the second quarter of 2026? Alnylam Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 22.1 % in its second quarter of 2026 a new company high.
Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2026.
Within the Healthcare sector 44 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. 427.
In a groundbreaking development that promises to redefine treatment standards, Alnylam Pharmaceuticals, Inc. has recently achieved a significant milestone in the realm of RNA interference (RNAi) therapeutics. The U.S. Food and Drug Administration (FDA) has granted approval for Qfitlia (fitusiran), marking it as the first siRNA therapeutic approved for the treatment of Hemophilia A and B. This approval not only represents a major step forward for patients grappling with these conditions but also underscores Alnylam s position as a leader in the innovative field of RNAi therapeutics. Qfitlia: A Game-Changer for Hemophilia Treatment Hemophilia, a genetic disorder that impedes the blood s ability to clot, has long posed treatment challenges, particularly for those suffering from Hemophilia A and B. Traditionally, treatment regimens have involved regular infusions of clotting factor concentrates. However, the recent FDA approval of Qfitlia introduces a new paradigm by targeting antithrombin, a protein that inhibits clot formation. By lowering antithrombin levels, Qfitlia aims to promote thrombin generation, ultimately rebalancing hemostasis and reducing the frequency of bleeding episodes in patients.
Breakthrough in RNAi Therapeutics: Alnylam s Nucresiran Shows Promise Amid Financial HurdlesIn an exciting development for the medical community, Alnylam Pharmaceuticals, Inc. a leader in RNAi therapeutics, has announced promising interim results from the Phase 1 study of their next-generation drug, nucresiran, at the American Heart Association Scientific Sessions 2024. These results have brought new hope in the treatment of transthyretin (ATTR) amyloidosis, a rare but severe condition characterized by the build-up of abnormal proteins, leading to organ damage. Significant Clinical Milestone The data presented in Chicago highlighted the effectiveness of a single dose of nucresiran in achieving a rapid knockdown of TTR (transthyretin), with effects sustained up to six months post-treatment. This outcome underscores the drug s potential in altering the disease course and improving patient outcomes. ATTR amyloidosis has long been a challenging condition with limited therapeutic options, and the prolonged efficacy of nucresiran could signify a meaningful advancement.
Financial Statements
Alnylam Pharmaceuticals Inc's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
